Cancer Biology Researcher Named 2015 AAAS Fellow
DNA is the basis of existence for all living organisms.
When something goes wrong in DNA, which is made up of thousands of other components, it can cause any number of problems in a persons overall health.
Thats why Carolyn Prices research is so important, and thats one of the reasons she has been named a 2015 fellow in the American Association for the Advancement of Science (AAAS).
Specifically, Price, PhD, who is a professor in the Department of Cancer Biology, is being honored for her contributions to the field of telomere biology in the area of telomere replication.
Her lab focuses on the structure and function of telomeres, the DNA-protein complexes that cap the ends of chromosomes. Telomeres are essential for genome stability as defects in their structure and/or failure to fully replicate the telomeric DNA lead to chromosome shortening and end-to-end fusion of chromosomes. This loss of telomere function can cause bone marrow failure and lung disease.
"Im honored to be selected for such a prestigious distinction, she says. "Many esteemed colleagues have been named AAAS fellows, and Im proud to be part of that group and happy that the importance of my research has been recognized.
Price received her PhD from the University of Colorado Medical Center in 1985 and completed her postdoctoral fellowship at the University of Colorado at Boulder in 1988, where she focused on telomere biology in Thomas Cechs lab.
The AAAS has awarded the distinction of fellow to 347 of its members this year. These individuals have been elevated to this rank because of their efforts toward advancing science applications that are deemed scientifically or socially distinguished.
Price and the additional new fellows, which include UC's David Lentz, PhD, from the McMicken College of Arts and Sciences, and Marc Cahay, PhD, from the College of Engineering and Applied Science, will be presented with an official certificate and a gold and blue rosette pin on Saturday, Feb. 13, 2016, at the AAAS Fellows Forum during the 2016 AAAS annual meeting in Washington, D.C.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.